Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NCT02791230 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1733

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin (TTR) Amyloid Cardiomyopathy

Interventions

DRUG: Tafamidis

Sponsor

Pfizer